Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Horses really can smell our fear, new study finds - 2When faith comes under fire: How Iran’s repression of religious minorities has increased
- 3'Pluribus' release date: Everything you need to know about the new series from 'Better Call Saul's' co-creator
- 4‘Raising 10 red flags’: Is Israel’s army exhausted?
- 5Step by step instructions to Guarantee Your Internet Promoting Degree Supplements Your Profession Objectives
- Israeli strike on Gaza City vehicle kills at least four, report says
- 6 U.S. States for Climbing
- Factbox-Weight-loss drug developers line up to tap lucrative market as competition heats up
- 100 new alien worlds: Scientists find hidden haul in data from NASA exoplanet-hunting spacecraft
- Astronaut on ISS captures spectacular orbital video of zodiacal light, auroras and the Pleiades
- Audits of Espresso Types: Which Mix Is for You?
- When preventable infections turn deadly behind bars | The Excerpt
- South Africa pushes for $200B investment
- RFK Jr. wants to scrutinize the vaccine schedule – but its safety record is already decades long
